PHGE BIOMX INC

BiomX Issues Statement Regarding Recent Common Stock Trading Activity

BiomX Issues Statement Regarding Recent Common Stock Trading Activity

NESS ZIONA, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today issued a statement in response to recent unusual market activity in its common stock.

The Company is not aware of any material developments in its business or affairs that have not been previously disclosed, nor, to its knowledge, of any other reason that would account for the recent unusual market activity in its common stock.

NYSE American LLC has contacted the Company in accordance with its usual practice and has advised that the Company issue this statement. The Company does not intend to make any further comment on market speculation or trading activity.

About BiomX

BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit , the content of which does not form a part of this press release.

Contacts:

BiomX, Inc.

Ben Cohen

Head Corporate Communications



EN
27/01/2026

Underlying

PHGEBIOMX INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIOMX INC

 PRESS RELEASE
Free
PHGE BIOMX INC

BiomX Issues Statement Regarding Recent Common Stock Trading Activity

BiomX Issues Statement Regarding Recent Common Stock Trading Activity NESS ZIONA, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today issued a statement in response to recent unusual market activity in its common stock. The Company is not aware of any material developments in its business or affairs that have not been previously disclosed, nor, to its knowledge, of any other reason that would account for the recen...

January 27, 2026 1 EN
 PRESS RELEASE
Free
PHGE BIOMX INC

BiomX Announces $3.0 Million Private Placement

BiomX Announces $3.0 Million Private Placement Proceeds to Support the Company’s Assessment of Opportunities to Advance BX011 and Ongoing Evaluation of Strategic Alternatives NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity (“Private Placement”) financing for expected gross proceeds of ...

December 29, 2025 1 EN
 PRESS RELEASE
Free
PHGE BIOMX INC

BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Inte...

BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review Following internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial  BiomX continues to see potential in BX011, its phage program for Staphylococcus aureus (S. aureus) infections associated with diabetic foot infections (DFI). The Company is also implementing cost cutting measures, while evaluating strategic alternatives NESS ZIONA, Israel, Dec. 08, 2025 (GLOBE NEWSWIRE) --  BiomX Inc. (NYSE American: PHGE) (“BiomX” ...

December 8, 2025 1 EN
 PRESS RELEASE
Free
PHGE BIOMX INC

BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis

BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift the clinical hold concerning the nebulizer device used in the Phase 2b trial An independent Data Monitoring Committee (DMC) completed a safety review following adverse events identified in the BX004 Phase 2b trial and recommended that the study continue with revised dosing Following the DMC review, the study protocol will be updated, and topline results are now expected in Q2 2026 N...

November 25, 2025 1 EN
 PRESS RELEASE
Free
PHGE BIOMX INC

BiomX Inc. Announces 1-for-19 Reverse Stock Split

BiomX Inc. Announces 1-for-19 Reverse Stock Split NESS ZIONA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it intends to effect a one-for-nineteen reverse split (the "Reverse Stock Split") of the Company’s common stock (the "Common Stock"). The Common Stock will continue to trade on the NYSE American under the existing symbol “PHGE” and will begin trading on a split-adjusted basis when the mar...

November 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch